BioDelivery Sciences Named to the Russell 3000® Index
June 20 2019 - 8:00AM
BioDelivery Sciences International, Inc. (NASDAQ: BDSI) is set
to be added to the broad-market Russell 3000® Index as well as
the Russell 2000® Index at the conclusion of the 2019 Russell
indexes annual reconstitution, effective July 1, 2019, according to
a preliminary list of additions posted June 7, 2019.
The annual Russell indexes reconstitution
captures the 4,000 largest US stocks as of May 10, 2019, ranking
them by total market capitalization. Membership in the US all-cap
Russell 3000 Index, which remains in place for one year, means
automatic inclusion in the Russell 2000 Index, as well as in the
appropriate growth and value style indexes. FTSE Russell determines
membership for its Russell indexes primarily by objective,
market-capitalization ranking, and style attributes.
"We are very proud to have been named to the
Russell 3000 and 2000 indexes and congratulate all of our employees
for their extraordinary work and achievements over the last year,”
stated Herm Cukier, CEO of BDSI. “We have made great strides
in transforming the Company into a rapidly growing commercial
enterprise, remain dedicated to sustaining this positive
trajectory, and welcome the heightened visibility and opportunity
resulting from inclusion in these widely followed benchmarks.”
Russell indexes are widely used by investment
managers and institutional investors as the basis for index funds
and as benchmarks for active investment strategies. Approximately
$9 trillion in assets are benchmarked against Russell’s US indexes.
Russell indexes are part of FTSE Russell, a leading global index
provider.
For more information on the Russell 3000 Index
and the Russell indexes reconstitution, go to the “Russell
Reconstitution” section on the FTSE Russell website.
ABOUT BIODELIVERY SCIENCES INTERNATIONAL,
INC.
BioDelivery Sciences International,
Inc. (NASDAQ: BDSI) is a commercial-stage specialty
pharmaceutical company dedicated to patients living with chronic
conditions. BDSI has built a portfolio of products that includes
utilizing its novel and proprietary BioErodible MucoAdhesive
(BEMA®) technology to develop and commercialize, either on its own
or in partnership with third parties, new applications of proven
therapies aimed at addressing important unmet medical needs. BDSI's
marketed products and those in development address serious and
debilitating conditions such as chronic pain, breakthrough cancer
pain, opioid dependence, and opioid-induced constipation.
ABOUT FTSE RUSSELL
FTSE Russell is a global index leader that
provides innovative benchmarking, analytics and data solutions for
investors worldwide. FTSE Russell calculates thousands of indexes
that measure and benchmark markets and asset classes in more than
70 countries, covering 98% of the investable market globally.
FTSE Russell index expertise and products are
used extensively by institutional and retail investors globally.
Approximately $16 trillion is currently benchmarked to FTSE Russell
indexes. For over 30 years, leading asset owners, asset managers,
ETF providers, and investment banks have chosen FTSE Russell
indexes to benchmark their investment performance and create ETFs,
structured products and index-based derivatives.
A core set of universal principles guides FTSE
Russell index design and management: a transparent
rules-based methodology is informed by independent committees of
leading market participants. FTSE Russell is focused on applying
the highest industry standards in index design and governance and
embraces the IOSCO Principles. FTSE Russell is also focused on
index innovation and customer partnerships as it seeks to enhance
the breadth, depth, and reach of its offering.
FTSE Russell is wholly owned by London Stock Exchange Group.
For more information, visit www.ftserussell.com
CAUTIONARY NOTE ON FORWARD-LOOKING
STATEMENTS
This press release and any statements of
employees, representatives, and partners of BDSI related thereto
contain, or may contain, among other things, certain
“forward-looking statements” within the meaning of the Private
Securities Litigation Reform Act of 1995. Such forward-looking
statements involve significant risks and uncertainties. Such
statements may include, without limitation, statements with respect
to the BDSI’s plans, objectives, projections, expectations and
intentions and other statements identified by words such as
“projects,” “may,” “will,” “could,” “would,” “should,” “believes,”
“expects,” “anticipates,” “estimates,” “intends,” “plans,”
“potential” or similar expressions. These statements are based upon
the current beliefs and expectations of the BDSI’s management and
are subject to significant risks and uncertainties, including those
detailed in the BDSI’s filings with the Securities and
Exchange Commission. Actual results may differ materially from
those set forth or implied in the forward-looking statements. These
forward-looking statements involve certain risks and uncertainties
that are subject to change based on various factors (many of which
are beyond the BDSI’s control) including those set forth in our
2018 annual report on Form 10-K filed with the US Securities
and Exchange Commission and subsequent filings. BDSI undertakes no
obligation to publicly update any forward-looking statements,
whether as a result of new information, future presentations or
otherwise, except as required by applicable law.
Contact:
Mary ColemanVice President, Investor Relations and Corporate
CommunicationsBioDelivery Sciences International,
Inc.mcoleman@bdsi.com
BioDelivery Sciences (NASDAQ:BDSI)
Historical Stock Chart
From Mar 2024 to Apr 2024
BioDelivery Sciences (NASDAQ:BDSI)
Historical Stock Chart
From Apr 2023 to Apr 2024